A novel PD1-CD40 bispecific antibody YH008 induces potent anti-tumor activity in vivo by PD1 dependent activation of CD40 signaling.

被引：0
|
作者：
Liu, Baihong [1 ]
Hui, Li [2 ]
Liu, Chonghui [1 ]
Li, Zhihong [3 ]
Pan, Fangxia [1 ]
Yang, Benny [1 ]
Lin, Qingcong [2 ]
机构：
[1] Biocytogen, Beijing, Peoples R China
[2] Biocytogen, Wakefield, MA USA
[3] Eucure Beijing Biopharma Co Ltd, Wakefield, MA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1852
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
    Hagerbrand, Karin
    Sundstedt, Anette
    Levin, Mattias
    de Coana, Yago Pico
    Varas, Laura
    Ljung, Lill
    Nilsson, Anneli
    Celander, Mona
    Jimenez, David Gomez
    Andersson, Hampus
    Lindstedt, Malin
    Ellmark, Peter
    CANCER RESEARCH, 2023, 83 (07)
  • [22] ABL503 (TJ-L14B), PD-L1X4-1BB BISPECIFIC ANTIBODY INDUCES SUPERIOR ANTI-TUMOR ACTIVITY BY PD-L1-DEPENDENT 4-1BB ACTIVATION WITH THE INCREASE OF 4-1BB+CD8+T CELLS IN TUMOR MICROENVIRONMENT
    Jung, Uijung
    Jeon, Jaehyoung
    Lee, Shinai
    Jin, Hyung-Seung
    Kim, Youngkwang
    Sung, Eunsil
    Kim, Hyunjoo
    Lim, Yangmi
    Won, Jonghwa
    Wang, Zhengyi
    Jiang, Wenqing
    Jung, Jaeho
    You, Gihoon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A935 - A935
  • [23] Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity
    Liu, Liu
    Zhang, Honghan
    Hou, Jie
    Zhang, Yuying
    Wang, Luosen
    Wang, Shijun
    Yao, Zhiying
    Xie, Tao
    Wen, Xiaoan
    Xu, Qinglong
    Dai, Liang
    Feng, Zhiqi
    Zhang, Pu
    Wu, Yaojun
    Sun, Hongbin
    Liu, Jun
    Yuan, Haoliang
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (06) : 4977 - 4997
  • [24] Uncovering the mechanism of synergistic anti-tumor effects in FAP-CD40+PD1-IL2v combination therapy
    Nguyen, Thuy Trinh
    Kunz, Leo
    de Matos, Ines Grazina
    Trumpfheller, Christine
    Umana, Pablo
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [25] PD1 AND LAG3 SYNERGIZE ON CD8+ T CELLS TO HINDER IFNg-DEPENDENT ANTI-TUMOR IMMUNITY
    Andrews, Lawrence
    Cardello, Carly
    Cui, Jian
    Workman, Creg
    Vignali, Dario
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A847 - A847
  • [26] A patient-derived anti-CD9 antibody induces tumor rejection and synergistically enhances anti-PD1 activity
    Schotte, Remko
    Villaudy, Julien
    Kedde, Martijn
    Pos, Wouter
    Wagner, Koen
    Neviani, Viviana
    Go, Daniel
    Yasuda, Etsuko
    Fatmawati, Christien
    Verdegaal, Els
    van Hal, Susan
    Claasen, Yvonne
    van Eenennaam, Hans
    van Helden, Pauline
    Gros, Piet
    van der Burg, Sjoerd
    Spits, Hergen
    CANCER RESEARCH, 2020, 80 (16)
  • [27] A patient-derived anti-CD9 antibody induces tumor rejection and synergistically enhances anti-PD1 activity
    Schotte, Remko
    Villaudy, Julien
    Pos, Wouter
    Wagner, Koen
    Neviani, Viviana
    Go, Daniel
    Fatmawati, Christien
    Verdegaal, Els
    van Hal, Susan
    Bru, Camille
    Claassen, Yvonne
    van Helden, Pauline
    van der Burg, Sjoerd
    Gros, Piet
    Spits, Hergen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, induces tumor localized immune cell activation in preclinical in vivo tumor model
    Andersson, Hampus
    Uddback, Ida
    Celander, Mona
    Johansson, Maria
    Ljung, Lill
    Nilsson, Anneli
    Shetty, Amulya Krishna
    Jimenez, David Gomez
    Levin, Mattias
    Fritzell, Sara
    von Schantz, Laura
    Lindstedt, Malin
    Hagerbrand, Karin
    Sundstedt, Anette
    Ellmark, Peter
    CANCER RESEARCH, 2024, 84 (06)
  • [29] A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity
    Ma, Hayley S.
    Poudel, Bibhav
    Roussos, Evanthia
    Sidhom, Torres John-William
    Robinson, Tara M.
    Christmas, Brian
    Scott, Blake
    Cruz, Kayla
    Woolman, Skylar
    Wall, Valerie Z.
    Armstrong, Todd
    Jaffee, Elizabeth M.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (03) : 428 - 442
  • [30] A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
    Cecile Geuijen
    Paul Tacken
    Liang-Chuan Wang
    Rinse Klooster
    Pieter Fokko van Loo
    Jing Zhou
    Arpita Mondal
    Yao-bin Liu
    Arjen Kramer
    Thomas Condamine
    Alla Volgina
    Linda J. A. Hendriks
    Hans van der Maaden
    Eric Rovers
    Steef Engels
    Floris Fransen
    Renate den Blanken-Smit
    Vanessa Zondag-van der Zande
    Abdul Basmeleh
    Willem Bartelink
    Ashwini Kulkarni
    Wilfred Marissen
    Cheng-Yen Huang
    Leslie Hall
    Shane Harvey
    Soyeon Kim
    Marina Martinez
    Shaun O’Brien
    Edmund Moon
    Steven Albelda
    Chrysi Kanellopoulou
    Shaun Stewart
    Horacio Nastri
    Alexander B. H. Bakker
    Peggy Scherle
    Ton Logtenberg
    Gregory Hollis
    John de Kruif
    Reid Huber
    Patrick A. Mayes
    Mark Throsby
    Nature Communications, 12
12345